Your session is about to expire
← Back to Search
Psilocybin for Depression in Alzheimer's
Study Summary
This trial will test whether the hallucinogenic drug psilocybin is safe and effective for treating depression in people with Mild Cognitive Impairment or early Alzheimer's Disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with schizophrenia, a psychotic disorder (unless it was caused by drugs or a medical condition), or bipolar I disorder in the past or currently.I have tried various treatments for my current depressive episode, including psychotherapy, medications, and possibly ECT.I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.I agree not to take medications like sildenafil within 72 hours before taking psilocybin.You have been diagnosed with depression, which can be mild or moderate based on a test called the Cornell Scale for Depression in Dementia. Or, you have been diagnosed with specific types of depression according to the DSM-5 diagnostic criteria.I am currently on antidepressants, antipsychotics, or MAO inhibitors.I have been diagnosed with depression or show signs of distress.I have no recent severe heart issues or uncontrolled high blood pressure.I have been diagnosed with early-stage Alzheimer's or mild cognitive impairment.I have a close family member with Schizophrenia, Psychotic Disorder, or Bipolar I.I have someone close who can discuss changes in my mood and behavior for the study.I have been diagnosed with early-stage Alzheimer's or mild cognitive impairment.You have a close friend or family member willing and able to serve the role of community observer / informant for data collection procedures.I am currently experiencing a depressive episode.I can attend long treatment sessions in Baltimore and follow-up meetings.I am currently experiencing a depressive episode.I have someone close who can discuss changes in my mood and behavior for the study.I have been diagnosed with Alzheimer's, early Alzheimer's, or Mild Cognitive Impairment.I can attend all required meetings in Baltimore for the study.I have been diagnosed with Alzheimer's or Mild Cognitive Impairment.I have a seizure disorder.I require insulin for my diabetes.
- Group 1: Psilocybin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 2 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 10 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 1 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is this research project being participated in by test subjects?
"Affirmative. The clinicaltrials.gov website verifies that this trial, initially posted on March 24th 2021, is currently enrolling participants. Up to 20 patients can be enrolled from a single facility."
Are there any vacancies for participants in this trial?
"This medical study, which has been actively searching for patients since 3/24/2021 and updated as recently as 3/9/2022 according to clinicaltrials.gov, is still in the process of recruitment."
Are there any analogous experiments to the current Psilocybin study?
"Currently, 33 medical studies exploring the use of Psilocybin are in progress with none at Phase 3. Most trials are situated in Vancouver, Washington but there are 36 sites across the United States participating."
Could I qualify to participate in this clinical research project?
"This clinical trial seeks 20 people with Alzheimer's disease, aged between 18 and 85. All enrollees must meet one of two criteria: they either possess a mild cognitive impairment or demonstrate symptoms that qualify them for a DSM-5 diagnosis; additionally, they must have Mini Mental State Examination scores ranging from 18 to 26 (inclusive), present higher than average Cornell Scale for Depression in Dementia scores (> 6) and secure the participation of an informant who is close to them."
Is this medical trial open to individuals aged twenty-five and older?
"According to the regulations of this clinical trial, persons 18 years or older and no more than 85 can participate."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Behavioral Pharmacology Research Unit: < 24 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger